MS-444 (BE-34776) is a HuR ( ELAVL1 ) inhibitor that blocks the cytoplasmic translocation of HuR and inhibits its dimerization. MS-444 reduces cytoplasmic HuR levels by preventing the binding of HuR to ARE-mRNA , without altering the total expression of HuR . MS-444 induces apoptosis , inhibits cell growth, angiogenesis and invasion, and also regulates immune function and microbiota. MS-444 effectively alters the number, size and invasiveness of tumors in various cancer models. MS-444 is tolerable to intraperitoneal injection in vivo and can be applied to research related to colorectal cancer , familial adenomatous polyposis, colitis-associated cancer and glioblastoma.
Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > CNS Neoplasm | Products > Disease Areas > Glioma | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Glioblastoma | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HuR | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > COX
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.